Article Text

Download PDFPDF
MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis
  1. Jean-Baptiste Ducloyer1,
  2. Angelique Caignard2,
  3. Ramzi Aidaoui3,
  4. Yolaine Ollivier4,
  5. Guillaume Plubeau2,
  6. Sonia Santos-Moskalyk5,
  7. Lindsay Porphyre6,
  8. Caroline Le Jeune7,
  9. Lionel Bihl8,
  10. Samy Alamine9,
  11. Romain Marignier10,
  12. Romain Bourcier11,
  13. Mathilde Ducloyer12,
  14. Michel Weber1,
  15. Guylène Le Meur1,
  16. Sandrine Wiertlewski13,
  17. Pierre Lebranchu1
  1. 1Ophtalmologie, Centre Hospitalier Universitaire de Nantes, Nantes, France
  2. 2Ophtalmologie, Centre Hospitalier Universitaire d'Angers, Angers, France
  3. 3Ophtalmologie, Centre Hospitalier de Mans, Le Mans, France
  4. 4Neurologie, Centre Hospitalier de Mans, Le Mans, France
  5. 5Ophtalmologie, Centre Hospitalier Départemental la Roche-sur-Yon Luçon Montaigu, La Roche-sur-Yon, France
  6. 6Ophtalmologie, Centre Hospitalier de Saint Nazaire, Saint Nazaire, France
  7. 7Ophtalmologie, Centre Hospitalier de Cholet, Cholet, France
  8. 8Ophtalmologie, Centre Hospitalier de Laval, Laval, France
  9. 9Ophtalmologie, Centre Hospitalier de Challans, Challans, France
  10. 10Neurologie, Centre Hospitalier Universitaire de Lyon, Lyon, France
  11. 11Neuroradiologie diagnostique et interventionnelle, Centre Hospitalier Universitaire de Nantes, Nantes, France
  12. 12Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France
  13. 13Neurologie, Centre Hospitalier Universitaire de Nantes, Nantes, France
  1. Correspondence to Dr Jean-Baptiste Ducloyer, Ophtalmologie, Centre Hospitalier Universitaire de Nantes, Nantes 44093, France; jeanbaptiste.ducloyer{at}chu-nantes.fr

Abstract

Objective What is the proportion of antibodies to myelin oligodendrocyte glycoprotein (MOG-Ab) in optic neuritis (ON) in adults and what would be the ON presentation for which MOG-Ab should be tested?

Methods Multicentric prospective study conducted during 1 year on all patients diagnosed with acute ON in all ophthalmological units in hospitals in a region in western France.

Results Sixty-five patients were included. MOG-Ab prevalence was 14% (9/65) during an acute ON and 13% (7/55) after exclusion of patients already diagnosed with multiple sclerosis (MS) (8) or MOG+ON (2). Compared with MS and clinically isolated syndrome, MOG+ON had no female preponderance (67% of men in case of MOG+ON and 22% of men in case of MS and clinically isolated syndrome, p<0.05) were more often bilateral (44% vs 3%, p<0.005) and associated with optic disc swelling (ODS) (78% vs 14%, p<0.001). To predict MOG+ON, the positive predictive values (PPVs) of male sex, ODS and bilateral involvement were 29% (95% CI 9% to 48%), 41% (95% CI 18% to 65%) and 40% (95% CI 10% to 70%), respectively, while the negative predictive values (NPV) were 93% (95% CI 86% to 100%), 96% (95% CI 90% to 100%) and 91% (95% CI 83% to 99%), respectively. The combined factor ‘ODS or bilateral or recurrent ON’ was the best compromise between PPV (31% (95% CI 14% to 48%)) and NPV (100% (95% CI 100% to 100%)).

Conclusion Among ON episodes, MOG-Ab were found in 14% of cases. MOG+ON occurred without female preponderance and was significantly associated with ODS and/or bilateral ON. Testing MOG-Ab only in patients presenting with ODS or bilateral or recurrent ON would limit MOG-Ab tests to fewer than half of all patients without the risk of missing any MOG+ON cases.

  • Optic neuritis
  • Myelin oligodendrocyte glycoprotein
  • Aquaporin-4
  • Neuromyelitis optica
  • Neuromyelitis optica spectrum disorders
  • Multiple sclerosis
  • Prevalence
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors J-BD designed the study; acquired, analysed and interpreted the data; wrote the draft; invited coauthors to revise the draft; and approved the final version to be published. PL and SW designed the study; acquired, analysed and interpreted the data; revised the draft; and approved the final version to be published. AC, RA, GP, YO, SS-M, LP, CLJ, LB, SA, RB, MD acquired the data, revised the draft and approved the final version to be published. RM, MW and GLM analysed and interpreted the data, revised the draft and approved the final version to be published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The study was approved by a national ethics committee (comité de protection des personnes Ile de France 2: projet de recherche n°2017-10-09 RIPH 3) and conducted in compliance with the Declaration of Helsinki.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.